Relay Therapeutics (NASDAQ:RLAY) Price Target Raised to $29.00

Relay Therapeutics (NASDAQ:RLAY) had its price objective increased by HC Wainwright from $28.00 to $29.00 in a report released on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Relay Therapeutics’ FY2027 earnings at ($1.60) EPS.

A number of other research analysts have also issued reports on RLAY. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Monday, July 6th. Citizens Jmp boosted their price target on shares of Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a report on Monday, August 10th. Zacks Research cut shares of Relay Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. JonesTrading upgraded shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.92.

Relay Therapeutics Price Performance

Shares of Relay Therapeutics stock opened at $19.44 on Thursday. The stock has a market cap of $4.26 billion, a PE ratio of -12.38 and a beta of 1.69. The firm has a fifty day moving average price of $18.86 and a 200 day moving average price of $14.35. Relay Therapeutics has a 1 year low of $3.43 and a 1 year high of $21.27.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.96 million. As a group, equities analysts expect that Relay Therapeutics will post -1.61 EPS for the current year.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, insider Donald A. Bergstrom sold 2,237 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $41,630.57. Following the transaction, the insider owned 407,660 shares in the company, valued at approximately $7,586,552.60. This trade represents a 0.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Thomas Catinazzo sold 1,459 shares of Relay Therapeutics stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total transaction of $27,151.99. Following the sale, the chief financial officer directly owned 158,285 shares in the company, valued at approximately $2,945,683.85. This trade represents a 0.91% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 409,639 shares of company stock valued at $7,233,399 over the last ninety days. Company insiders own 5.04% of the company’s stock.

Institutional Investors Weigh In On Relay Therapeutics

A number of hedge funds have recently modified their holdings of the business. Torren Management LLC purchased a new position in shares of Relay Therapeutics in the fourth quarter worth about $30,000. KBC Group NV acquired a new position in Relay Therapeutics during the first quarter worth about $34,000. Allworth Financial LP purchased a new stake in Relay Therapeutics during the 2nd quarter valued at about $34,000. Smartleaf Asset Management LLC grew its stake in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Relay Therapeutics during the 4th quarter valued at about $46,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics News Summary

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Zacks Research upgraded Relay Therapeutics from “Strong Sell” to “Hold,” removing a notably bearish rating overhang. Zacks Research rating update
• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $29 price target, implying meaningful upside from the recent share price. Its forecasts call for continued quarterly losses but do not indicate a sharp deterioration in the longer-term earnings outlook. MarketBeat analyst estimates
• Neutral Sentiment: HC Wainwright expects Relay Therapeutics to remain unprofitable, forecasting EPS of $(0.39) in the first quarter of 2027, $(0.40) in the second and third quarters, and $(0.41) in the fourth quarter. Its FY2027 loss estimate is $(1.60) per share, matching the current full-year consensus estimate.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $(1.57) from $(1.50), reduced its third-quarter 2026 estimate to $(0.37) from $(0.36), and cut its fourth-quarter estimate to $(0.38) from $(0.37). The revisions reinforce concerns about ongoing cash use and the timing of profitability.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.